EG382275 Inhibitors
EG382275 inhibitors are a class of chemical compounds developed to specifically target and inhibit the activity of EG382275, a molecule likely involved in cellular processes such as enzymatic reactions or regulatory signaling pathways. EG382275 is thought to play a role in facilitating key cellular functions, potentially through interactions with proteins, enzymes, or other biomolecules. By modulating these interactions, EG382275 may influence various processes like signal transduction, protein modification, or metabolic regulation. Inhibition of EG382275 disrupts its natural function, leading to alterations in the biochemical pathways in which it participates. These inhibitors are crucial for exploring the biological significance of EG382275 and understanding how its activity regulates cellular homeostasis and other vital functions.
Structurally, EG382275 inhibitors are designed to interact with specific functional regions of the EG382275 molecule, such as its catalytic or binding domains. Competitive inhibitors typically block the active site, preventing EG382275 from engaging with its substrates, while non-competitive inhibitors may bind to alternative sites, causing conformational changes that reduce the molecule's activity. By inhibiting EG382275, researchers can investigate the downstream effects on cellular signaling and biochemical networks that depend on its function. This research provides insights into the regulatory mechanisms controlled by EG382275 and highlights its role in processes such as protein-protein interactions, enzymatic regulation, and intracellular communication. The study of EG382275 inhibitors allows for a better understanding of how specific molecular components contribute to the complex regulation of cellular pathways, aiding in the dissection of key processes required for cellular maintenance and regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor, modulating chromatin structure. Trichostatin A could impact the expression of Gm5168 by influencing histone acetylation dynamics, potentially affecting spermatid development and meiotic cell cycle through altered chromatin accessibility. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Microtubule destabilizer disrupting spindle dynamics. Nocodazole might indirectly inhibit Gm5168 by perturbing the meiotic cell cycle through disruption of microtubule-dependent processes, potentially impacting synaptonemal complex formation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor affecting PI3K-AKT signaling. Wortmannin could indirectly influence Gm5168 by modulating the PI3K pathway, potentially impacting spermatid development and meiotic cell cycle through altered signaling cascades. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
CDK inhibitor affecting cell cycle regulation. Roscovitine might impact Gm5168 by modulating cell cycle progression, potentially influencing meiotic cell cycle and spermatid development through the regulation of CDK-related processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor affecting MAPK signaling. SB-203580 could indirectly influence Gm5168 by modulating the p38 MAPK pathway, potentially impacting spermatid development and meiotic cell cycle through altered signaling cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting PI3K-AKT signaling. LY294002 could indirectly influence Gm5168 by modulating the PI3K pathway, potentially impacting spermatid development and meiotic cell cycle through altered signaling cascades. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
HSP90 inhibitor affecting protein folding. Geldanamycin might impact Gm5168 by modulating protein folding and stability, potentially influencing synaptonemal complex and meiotic cell cycle through altered chaperone-mediated processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting MAPK signaling. JNK Inhibitor II could indirectly influence Gm5168 by modulating the JNK pathway, potentially impacting spermatid development and meiotic cell cycle through altered signaling cascades. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor affecting protein degradation. MG-132 might impact Gm5168 by modulating proteasomal activity, potentially influencing synaptonemal complex and meiotic cell cycle through altered protein turnover and degradation processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor affecting mTOR signaling. Rapamycin could indirectly influence Gm5168 by modulating the mTOR pathway, potentially impacting spermatid development and meiotic cell cycle through altered signaling cascades. | ||||||